Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - HYPERION THERAPEUTICS INC | Financial_Report.xls |
| 10-Q - FORM 10-Q - HYPERION THERAPEUTICS INC | d383906d10q.htm |
| EX-32.2 - EX32.2 - HYPERION THERAPEUTICS INC | d383906dex322.htm |
| EX-10.4 - EX-10.4 - HYPERION THERAPEUTICS INC | d383906dex104.htm |
| EX-31.2 - EX-31.2 - HYPERION THERAPEUTICS INC | d383906dex312.htm |
| EX-31.1 - EX-31.1 - HYPERION THERAPEUTICS INC | d383906dex311.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Hyperion Therapeutics, Inc. (“Hyperion”) for the quarter ended June 30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Donald J. Santel, Chief Executive Officer and President of Hyperion, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Hyperion.
Dated: September 7, 2012
| /s/ Donald J. Santel |
| Donald J. Santel |
| Chief Executive Officer and President |
| (Principal Executive Officer) |